CHRS - Company ID 0001512762
The table below shows Coherus BioSciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $12.31M | $11.57M | $10.25M | $7.60M | $6.05M | $10.30M |
| Cost of revenue | $3.81M | $3.72M | $3.40M | $2.65M | $2.73M | $1.81M |
| Gross profit | - | - | - | - | - | - |
| R&D | $21.54M | $27.25M | $26.31M | $24.36M | $22.05M | $20.60M |
Coherus BioSciences, Inc. reported annual revenue of $42.17M for fiscal year 2025. That is up 59.8% from $26.39M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $190.11M (FY 2016) to $42.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $23.10M |
| $24.93M |
| $26.04M |
| $26.02M |
| $28.13M |
| $27.52M |
| Operating income | -$36.15M | -$44.33M | -$45.49M | -$45.44M | -$46.86M | -$39.63M |
| Income tax | - | - | - | - | - | - |
| Net income | -$38.33M | -$35.53M | $297.77M | -$56.57M | -$10.75M | -$12.92M |
| EPS (diluted) | -$0.28 | -$0.31 | $2.57 | -$0.49 | -$0.09 | -$0.11 |